United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - phenylephrine hydrochloride; ascorbic acid; paracetamol - powder - 1.67mg/1gram ; 6.67mg/1gram ; 100mg/1gram

Malta - English - Medicines Authority

glaxosmithkline consumer health-care uk trading limited 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - phenylephrine hydrochloride, paracetamol - powder for oral solution - phenylephrine hydrochloride 10 mg paracetamol 600 mg - analgesics

Malta - English - Medicines Authority

glaxosmithkline consumer health-care uk trading limited 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - phenylephrine hydrochloride, paracetamol, ascorbic acid - powder for oral solution - phenylephrine hydrochloride 10 mg paracetamol 1000 mg ascorbic acid 40 mg - analgesics

Malta - English - Medicines Authority

glaxosmithkline consumer health-care uk trading limited 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - phenylephrine, paracetamol - powder for oral solution - phenylephrine 10 mg paracetamol 600 mg - analgesics

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; poliovirus, quantity: 80 dagu; pertussis toxoid, quantity: 50 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 16 microgram/ml; poliovirus, quantity: 16 dagu; poliovirus, quantity: 64 dagu - injection, suspension - excipient ingredients: aluminium phosphate; sodium chloride; aluminium hydroxide hydrate; neomycin sulfate; polymyxin b sulfate; water for injections; glucose monohydrate; polysorbate 80; ascorbic acid; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inosit - infanrix hexa is indicated for primary immunisation of infants from the age of 6 weeks against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and haemophilus influenzae type b. infanrix hexa is also indicated for use as booster dose if boosting with hepatitis b, poliomyelitis, and haemophilus influenzae type b, as well as diphtheria, tetanus and pertussis is required. refer to dosage and administration for further information.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mupirocin, quantity: 22 mg/g - ointment - excipient ingredients: macrogol 3350; macrogol 400 - bacrtoban (mupirocin) ointment is indicated for the topical treatment of mild impetigo.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 8 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.